Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

The company’s shares closed yesterday at $29.89. Olson covers the Healthcare sector, focusing on stocks such as Jasper Therapeutics, Viking Therapeutics, and Bicycle Therapeutics. According to ...

Amgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...

ULTY offers a 101% distribution yield but has only delivered 2.4% total performance since inception. Read why ULTY ETF's ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

根据最近的SEC文件显示，Viking Therapeutics, Inc. (NASDAQ:VKTX)的董事Macartney Lawson最近进行了几笔涉及公司股票的交易。2023年11月8日，Lawson以平均每股68.67美元的价格出售了2,000股Viking Therapeutics普通股，总销售额约为137,333美元。 除了出售股票外，Lawson还通过行权以每股5.80美元的价格 ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...